Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer.

ABSTRACT:

Background

Approximately 25% of patients with early-stage breast cancer experience cancer progression throughout the disease course. Alterations in TMEM240 in breast cancer were identified and investigated to monitor treatment response and disease progression.

Methods

Circulating methylated TMEM240 in the plasma of breast cancer patients was used to monitor treatment response and disease progression. The Cancer Genome Atlas (TCGA) data in Western countries and Illumina methylation arrays in Taiwanese breast cancer patients were used to identify novel hypermethylated CpG sites and genes related to poor hormone therapy response. Quantitative methylation-specific PCR (QMSP), real-time reverse transcription PCR, and immunohistochemical analyses were performed to measure DNA meth

SUBMITTER: Lin RK 

PROVIDER: S-EPMC9204905 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature